Medivation licenses exclusive rights to CureTech's Phase II cancer project pidilizumab
CureTech Ltd. granted Medivation Inc. exclusive global rights to develop and sell pidilizumab (CT011) in all indications, including cancer. The anti-PD-1 antibody is in Phase II studies for blood and solid tumors.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.